CoMedical Diagnostics (688468.SH): CICC Kangrui plans to reduce its shareholding by no more than 0.67%.

Caijing APP news, Kemei Diagnostics (688468.SH) announced that shareholder Zhongjin Kangrui Yi Phase (Ningbo) Equity Investment Fund Partnership Enterprise (limited partnership) (referred to as "Zhongjin Kangrui") intends to reduce its holdings of the company's shares by no more than 2.7 million shares through centralized bidding trading as the fund is nearing expiration, and the proportion of the intended reduction of shares held by the company does not exceed 0.67% of the total share capital of the company.